• Je něco špatně v tomto záznamu ?

Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer's disease and other tauopathies

N. Annadurai, JB. De Sanctis, M. Hajdúch, V. Das

. 2021 ; 343 (-) : 113756. [pub] 20210512

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003807

Alzheimer's disease (AD) is characterised by the accumulation of intracytoplasmic aggregates of tau protein, which are suggested to spread in a prion-like manner between interconnected brain regions. This spreading is mediated by the secretion and uptake of tau from the extracellular space or direct cell-to-cell transmission through cellular protrusions. The prion-like tau then converts the endogenous, normal tau into pathological forms, resulting in neurodegeneration. The endoplasmic reticulum/Golgi-independent tau secretion through unconventional secretory pathways involves delivering misfolded and aggregated tau to the plasma membrane and its release into the extracellular space by non-vesicular and vesicular mechanisms. Although cytoplasmic tau was thought to be released only from degenerating cells, studies now show that cells constitutively secrete tau at low levels under physiological conditions. The mechanisms of secretion of tau under physiological and pathological conditions remain unclear. Therefore, a better understanding of these pathways is essential for developing therapeutic approaches that can target prion-like tau forms to prevent neurodegeneration progression in AD. This review focuses on unconventional secretion pathways involved in the spread of tau pathology in AD and presents these pathways as prospective areas for future AD drug discovery and development.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003807
003      
CZ-PrNML
005      
20220127145836.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.expneurol.2021.113756 $2 doi
035    __
$a (PubMed)33989658
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Annadurai, Narendran $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 77900 Olomouc, Czech Republic
245    10
$a Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer's disease and other tauopathies / $c N. Annadurai, JB. De Sanctis, M. Hajdúch, V. Das
520    9_
$a Alzheimer's disease (AD) is characterised by the accumulation of intracytoplasmic aggregates of tau protein, which are suggested to spread in a prion-like manner between interconnected brain regions. This spreading is mediated by the secretion and uptake of tau from the extracellular space or direct cell-to-cell transmission through cellular protrusions. The prion-like tau then converts the endogenous, normal tau into pathological forms, resulting in neurodegeneration. The endoplasmic reticulum/Golgi-independent tau secretion through unconventional secretory pathways involves delivering misfolded and aggregated tau to the plasma membrane and its release into the extracellular space by non-vesicular and vesicular mechanisms. Although cytoplasmic tau was thought to be released only from degenerating cells, studies now show that cells constitutively secrete tau at low levels under physiological conditions. The mechanisms of secretion of tau under physiological and pathological conditions remain unclear. Therefore, a better understanding of these pathways is essential for developing therapeutic approaches that can target prion-like tau forms to prevent neurodegeneration progression in AD. This review focuses on unconventional secretion pathways involved in the spread of tau pathology in AD and presents these pathways as prospective areas for future AD drug discovery and development.
650    _2
$a Alzheimerova nemoc $x metabolismus $x patologie $7 D000544
650    _2
$a zvířata $7 D000818
650    _2
$a mozek $x metabolismus $x patologie $7 D001921
650    _2
$a mezibuněčná komunikace $x fyziologie $7 D002450
650    _2
$a lidé $7 D006801
650    _2
$a patologická konformace proteinů $x metabolismus $x patologie $7 D066263
650    _2
$a tauopatie $x metabolismus $x patologie $7 D024801
650    _2
$a proteiny tau $x metabolismus $7 D016875
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a De Sanctis, Juan B $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 77900 Olomouc, Czech Republic
700    1_
$a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 77900 Olomouc, Czech Republic
700    1_
$a Das, Viswanath $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 5, 77900 Olomouc, Czech Republic. Electronic address: viswanath.das@upol.cz
773    0_
$w MED00001749 $t Experimental neurology $x 1090-2430 $g Roč. 343, č. - (2021), s. 113756
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33989658 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145832 $b ABA008
999    __
$a ok $b bmc $g 1751312 $s 1154956
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 343 $c - $d 113756 $e 20210512 $i 1090-2430 $m Experimental neurology $n Exp Neurol $x MED00001749
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...